In this issue:
Tumour deposits should be included in staging
Real-world use of adjuvant oxaliplatin in CRC
Cetuximab in RAS wild-type colon cancer
Worse post-progression survival in BRAF-mutant CRC
KRAS codon 12 mutations and OS in mCRC
Primary tumour resection not recommended in mCRC
Tumour molecular subtype and firstline treatment
Capecitabine + bevacizumab maintenance not cost-effective
Predictive value of geriatric parameters
Nomogram to estimate12-week probability of death
Nivolumab shows promise for anal cancer
Please login below to download this issue (PDF)